EXEL — Exelixis, Inc.

Exelixis Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: Approximately $599 million for Q4 2025, with cabozantinib franchise revenues of $546.6 million.
• CABOMETYX Revenues: $544.7 million in Q4 2025, with a 6% year-over-year growth. Full-year 2025 revenues reached approximately $2.12 billion, a 17% increase from 2024.
• Gross to Net Deductions: 28.5% in Q4 2025, lower than Q3 2025 due to decreased PHS and 340B volume. Projected gross to net for 2026 is estimated between 31% and 32%.
• Operating Expenses: Approximately $363 million in Q4 2025, up from $341 million in Q3 2025, driven by higher manufacturing and marketing costs.
• Net Income: GAAP net income of $244.5 million ($0.92 per share) and non-GAAP net income of $259.5 million ($0.97 per share).
• Cash Position: Cash and marketable securities totaled approximately $1.66 billion. The company repurchased $954 million of stock in 2025.

2. Strategic Updates and Business Highlights

• Cabozantinib Performance: Continued strong performance in renal cell carcinoma (RCC) and neuroendocrine tumors, maintaining market leadership in these areas.
• Zanzalintinib (Zanza): NDA accepted for zanza in combination with atezolizumab for third-line colorectal cancer (CRC), with a PDUFA date set for December 3, 2026. Seven pivotal trials are ongoing or planned for zanza.
• Expansion of Sales Team: A GI sales team was expanded to enhance market penetration for CABOMETYX and prepare for the zanza launch.
• Pipeline Development: The IND pipeline is robust with several promising candidates, focusing on identifying potential franchise molecules beyond cabozantinib and zanzalintinib.

3. Forward Guidance and Outlook

• 2026 Financial Guidance: Exelixis expects continued growth in both the cabozantinib and zanzalintinib franchises, with significant revenue contributions anticipated from both products.
• Market Expansion: The company aims to leverage its existing sales force and new hires to capture greater market share, particularly in community settings.

4. Bad News, Challenges, or Points of Concern

• Gross to Net Deductions: The decline in gross to net deductions in Q4 2025 raises concerns about pricing pressures, particularly in the 340B segment.
• Competitive Landscape: The oncology market remains highly competitive, with ongoing trials that could challenge cabozantinib's market share, particularly in RCC.
• Regulatory Risks: Potential uncertainties related to the FDA review process for zanza, including the possibility of an advisory committee review.

5. Notable Q&A Insights

• Zanza Launch Timing: The company is optimistic about maintaining small manufacturer exemptions during the zanza launch, but specifics on timing remain uncertain.
• 340B Purchasing Behavior: Variability in 340B purchasing behavior is expected to continue, impacting gross to net metrics.
• Market Size for STELLAR-316: The potential patient population for the STELLAR-316 trial is estimated at 20,000 to 25,000, focusing on MRD-positive patients post-definitive therapy.
• Commercial Strategy for Non-Liver Metastases: Positive data from ongoing trials could significantly impact commercial strategies and communications with physicians, particularly for underserved patient populations.

Overall, Exelixis demonstrated strong financial performance in Q4 2025, with promising developments in its pipeline and strategic initiatives aimed at expanding its oncology franchises. However, the company faces challenges from competitive pressures and regulatory uncertainties as it prepares for upcoming product launches.